141408-45-9 Usage
Uses
Used in Pharmaceutical Research:
(S)-4-(benzyloxy)-2-((tert-butoxycarbonyl)(methyl)amino)-4-oxobutanoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason] its ability to modulate biological processes and potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-4-(benzyloxy)-2-((tert-butoxycarbonyl)(methyl)amino)-4-oxobutanoic acid is used as a building block for [application reason] its unique structural features, which include a benzyl group, a tert-butoxycarbonyl group, a methylamino group, and a carboxylic acid group.
Used in Drug Development:
(S)-4-(benzyloxy)-2-((tert-butoxycarbonyl)(methyl)amino)-4-oxobutanoic acid is used as a potential candidate in the development of new drugs and treatments for [application reason] its potential therapeutic properties and ability to modulate biological processes.
Used in the Development of Medical Treatments:
In the medical industry, (S)-4-(benzyloxy)-2-((tert-butoxycarbonyl)(methyl)amino)-4-oxobutanoic acid is used as a compound with potential applications in the development of new treatments for various medical conditions due to [application reason] its potential therapeutic properties and ability to modulate biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 141408-45-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,1,4,0 and 8 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 141408-45:
(8*1)+(7*4)+(6*1)+(5*4)+(4*0)+(3*8)+(2*4)+(1*5)=99
99 % 10 = 9
So 141408-45-9 is a valid CAS Registry Number.
141408-45-9Relevant academic research and scientific papers
The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain
Brown, Alan D.,Bagal, Sharan K.,Blackwell, Paul,Blakemore, David C.,Brown, Bruce,Bungay, Peter J.,Corless, Martin,Crawforth, James,Fengas, David,Fenwick, David R.,Gray, Victoria,Kemp, Mark,Klute, Wolfgang,Malet Sanz, Laia,Miller, Duncan,Murata, Yoshihisa,Payne, C. Elizabeth,Skerratt, Sarah,Stevens, Edward B.,Warmus, Joseph S.
supporting information, p. 230 - 239 (2018/12/11)
The voltage gated sodium channel NaV1.8 has been postulated to play a key role in the transmission of pain signals. Core hopping from our previously reported phenylimidazole leads has allowed the identification of a novel series of benzimidazole NaV1.8 blockers. Subsequent optimization allowed the identification of compound 9, PF-06305591, as a potent, highly selective blocker with an excellent preclinical in vitro ADME and safety profile.
Synthesis and Biological Activity of CCK Heptapeptide Analogues. Effects of Conformational Constraints and Standard Modifications on Receptor Subtype Selectivity, Functional Activity in Vitro, and Appetite Suppression in Vivo
Holladay, Mark W.,Bennett, Michael J.,Tufano, Michael D.,Lin, C. W.,Asin, Karen E.,et al.
, p. 2919 - 2928 (2007/10/02)
A series of modifications of the CCK7 analogue (des-NH2)Tyr(SO3-)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 was prepared and tested for binding to guinea pig CCK-A and CCK-B receptors and in CCK-A-mediated functional assays.Selected analogues also were teste
